Statin use and risk of prostate cancer: Results from a population-based epidemiologic study

Statin use and risk of prostate cancer: Results from a population-based epidemiologic study
复制标题

DOI:
10.1093/aje/kwn141
复制
发表时间:
2008-08-01
影响因子:
5
通讯作者:
Stanford, Janet L.
Stanford, Janet L.
中科院分区:
医学2区
文献类型:
--
作者:
Agalliu, Ilir;Salinas, Claudia A.;Stanford, Janet L.

文献摘要

被引文献

相似文献

他汀类药物使用与前列腺癌风险相关的流行病学研究尚未得出结论。然而,最近的证据表明,长期使用可能会降低更晚期疾病的风险。作者对2002-2005年诊断的1,001例前列腺癌病例和来自华盛顿金郡的942例年龄匹配的对照进行了一项基于人群的研究,以评估与他汀类药物使用相关的风险。Logistic回归用于生成曾经使用、当前使用和使用持续时间的比值比。在他汀类药物使用和前列腺癌风险之间没有发现总体相关性(当前使用的比值比(OR)= 1.0,95%置信区间(CI):0.8,1.2;使用> 10年的OR = 1.1,95% CI:0.7,1.8),即使是更晚期疾病的病例。然而,与他汀类药物使用相关的风险被体重指数修正(相互作用p = 0.04)。肥胖男性(BMI >= 30 kg/m2)使用他汀类药物的风险高于肥胖非使用者(OR = 1.5,95%CI:1.0,2.2),长期使用的相关性更强(OR = 1.8,95%CI:1.1,3.0,>= 5年使用)。虽然他汀类药物的使用与总体前列腺癌风险无关,但肥胖男性中他汀类药物使用相关风险增加的发现,特别是长期使用,值得进一步研究。
Epidemiologic studies of statin use in relation to prostate cancer risk have been inconclusive. Recent evidence, however, suggests that longer-term use may reduce risk of more advanced disease. The authors conducted a population-based study of 1,001 incident prostate cancer cases diagnosed in 2002-2005 and 942 age-matched controls from King County, Washington, to evaluate risk associated with statin use. Logistic regression was used to generate odds ratios for ever use, current use, and duration of use. No overall association was found between statin use and prostate cancer risk (odds ratio (OR) = 1.0, 95% confidence interval (CI): 0.8, 1.2 for current use; OR = 1.1, 95% CI: 0.7, 1.8 for > 10 years' use), even for cases with more advanced disease. Risk related to statin use, however, was modified by body mass index (interaction p = 0.04). Obese men (BMI >= 30 kg/m(2)) who used statins had an increased risk (OR = 1.5, 95% CI: 1.0, 2.2) relative to obese nonusers, with a stronger association for longer-term use (OR = 1.8, 95% CI: 1.1, 3.0 for >= 5 years' use). Although statin use was not associated with overall prostate cancer risk, the finding of an increased risk associated with statin use among obese men, particularly use for extended durations, warrants further investigation.